Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms - Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms

Division of Urology, Kobe University Graduate School of Medicine0 sites200 target enrollmentSeptember 1, 2012

Overview

No summary available.

Registry

who.int

Start Date

September 1, 2012

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Division of Urology, Kobe University Graduate School of Medicine

•1\) patients are having the disease other than a benign prostatic hyperplasia (prostate cancer, bladder tumors, bladder stones, prostatitis, bladder neck sclerosis, patients, etc.) 2\) Patients have received TUR\-P, balloon dilation, urethral stent, hyperthermia, or radiation therapy to the pelvis, within 6 months of the start of the study 3\) Self\-catheterization 4\) Patients with urinary tract infection 5\) Patients with concomitant disease and other nervous system diseases, and it suspected to be neurogenic bladder 6\) Patients with concomitant severe ischemic heart disease, cerebrovascular disease, liver dysfunction, renal dysfunction. 7\) Patients with hypotension 8\) Patients are having hypersensitivity to silodosin, naftopidil or taking vardenafil hydrochloride 9\) Patients have treated with hormonal drug within 6 months 10\) Patients treated with drugs other than tamsulosin is considered effective on urinary symptoms within a week 11\) Patients was deemed by the physician as inappropriate to attend